Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,697,204 papers from all fields of science
Search
Sign In
Create Free Account
Liposomal Cytarabine-Daunorubicin CPX-351
Known as:
CPX-351
, Cytarabine-Daunorubicin Liposome for Injection
, Liposomal AraC-Daunorubicin CPX-351
A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposomal…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia
L. Agresta
,
M. O’Brien
,
+14 authors
M. Absalon
Blood
2019
Corpus ID: 209292281
Despite significant advances in AML therapy over the past decades, 30-40% of all young patients with AML will suffer a relapse…
Expand
2019
2019
PF263 DEEP RESPONSE AFTER CPX-351 TREATMENT IN T-AML AND MRC-AML: A REPORT FROM A MULTICENTRIC FRENCH COHORT
Edmond Chiche
,
S. Bertoli
,
+12 authors
T. Cluzeau
HemaSphere
2019
Corpus ID: 196553537
2019
2019
PB1733 OUTCOMES WITH CPX-351 VERSUS 7+3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK/SECONDARY AML: EXPLORATORY ANALYSIS OF A PHASE 3 STUDY
E. Ritchie
,
T. L. Lin
,
+7 authors
J. Cortes
HemaSphere
2019
Corpus ID: 196568589
2019
2019
PF293 PHASE 3 EXPLORATORY ANALYSIS OF OUTCOMES IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK/SECONDARY AML WHO ACHIEVED REMISSION WITH CPX-351 VERSUS 7+3 INDUCTION
S. Faderl
,
G. Schiller
,
R. Ryan
,
M. Chiarella
,
J. Cortes
HemaSphere
2019
Corpus ID: 196562466
2019
2019
Liposomales Medikament erhöht Überlebenschancen bei sekundärer AML
Christian Behrend
Im Fokus Onkologie
2019
Corpus ID: 189276864
Sekundäre akute myeloische Leukämien (AML) sind mit einer ungünstigen Prognose verbunden. US-Forscher haben untersucht, ob CPX…
Expand
2018
2018
A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia
M. Absalon
,
Erin H. Breese
,
+9 authors
J. Perentesis
Blood
2018
Corpus ID: 59263623
Background: CPX-351 (Vyxeos®) is a liposomal nanoparticle of cytarabine and daunorubicin in a 5:1 molar ratio currently FDA…
Expand
Review
2017
Review
2017
A Review of Acute Myeloid Leukemia Cancer and the Mechanism of Cytarabine as an Effective Chemotherapeutic AgentMelanie
M. Matthews
,
K. Dunham
,
Cai-yun Wang
2017
Corpus ID: 80425440
Normal cells •Reproduce themselves only when and where they are needed. •Stick together in the right place in the body or…
Expand
2016
2016
Abstract 287: CPX-351 cytotoxicity against fresh AML blasts is increased for FLT3-ITD+ cells and correlates with drug uptake and clinical outcomes
M. Gordon
,
P. Tardi
,
L. Mayer
,
J. Tyner
2016
Corpus ID: 79380426
2010
2010
CPX-351: A randomized phase IIb study first-relapse patients younger than age 65.
J. Kolitz
,
J. Cortes
,
Kim H. Paulsen
,
A. Louie
2010
Corpus ID: 78872346
TPS275 Background: CPX-351 is a liposomal formulation that co-encapsulates cytarabine and daunorubicin enabling in vivo delivery…
Expand
2010
2010
Leukemia Cell–Selective Uptake of Cytarabine and Daunorubicin in the Bone Marrow Compartment Mediated by CPX-351 Liposome Injection
Wahseng Lim
,
P. Tardi
,
+4 authors
L. Mayer
2010
Corpus ID: 72055938
Abstract Background Anticancer drug combinations such as cytarabine plus daunorubicin can act synergistically, additively or…
Expand